Targeted delivery of CYP2E1 recombinant adenovirus to malignant melanoma by bone marrow-derived mesenchymal stem cells as vehicles

Anti-Cancer Drugs

Volumn 25, Issue 3, 2014, Pages 303-314

  Wang, Jishi ^a   Ma, Dan ^a   Li, Yan ^a   Yang, Yuan ^a   Hu, Xiaoyan ^a   Zhang, Wei ^a   Fang, Qin ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus; Bone marrow derived mesenchymal stem cells; CYP450; DTIC; Gene directed enzyme prodrug therapy

Indexed keywords

ADENOVIRIDAE; ADOLESCENT; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BONE MARROW; CELL LINE, TUMOR; CELL MOVEMENT; CYTOCHROME P-450 CYP2E1; DACARBAZINE; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; MALE; MELANOMA; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; YOUNG ADULT;

EID: 84895076264     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000046     Document Type: Article

References (32)

1. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-1416.
2. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 2000; 60: 3761-3769.
3. Krishna R, Mayer DL. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res 1997; 57: 5246-5253.
4. Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA, et al. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies. J Clin Oncol 2000; 18: 1124-1134.
5. Hasinoff BB, Chee GL, Thampatty P, Allan WP, Yalowich JC. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothcin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis. Anticancer Drugs 1999; 10: 47-54.
6. Weyel D, Sedlacek HH, Muller R, Brusselbach S. Secreted human b-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther 2000; 7: 224-231.
7. Springer CJ, Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Invest 2000; 105: 1161-1167.
8. Hamstra DA, Rehemtulla A. Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/furin family of propeptidases. Hum Gene Ther 1999; 10: 235-248.
9. Rigg A, Sikora K. Genetic prodrug activation therapy [Review]. Mol Med Today 1997; 3: 359-366.
10. Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM, et al. New prodrug activation gene therapy for cancer using cytochrome p450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther 1998; 9: 1261-1273.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
12. Kuznetsov SA, Friedenstein AJ, Robey PG. Factors required for bone marrow stromal fibroblast colony formation in vitro. Br J Haematol 1997; 97: 561-570.
13. Kassem M, Kristiansen M, Abdallah BM. Mesenchymal stem cells: cell biology and potential use in therapy. Basic Clin Pharmacol Toxicol 2004; 95: 209-214.
14. Kon E, Muraglia A, Corsi A, Bianco P, Marcacci M, Martin I, et al. Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones. J Biomed Mater Res 2000; 49: 328-337.
15. Otto WR, Rao J. Tomorrow's skeleton staff: mesenchymal stem cells and the repair of bone and cartilage. Cell Prolif 2004; 37: 97-110.
16. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-b delivery into tumors. Cancer Res 2002; 62: 3603-3608.
17. Korbling M, Estrov Z. Adult stem cells for tissue repair - a new therapeutic concept? N Engl J Med 2003; 349: 570-582.
18. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65: 3307-3318.
19. Stoff-Khalili MA, Rivera AA, Mathis JM, Banerjee NS, Moon AS, Hess A, et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007; 105: 157-167.
20. Chiu RC. Bone-marrow stem cells as a source for cell therapy. Heart Fail Rev 2003; 8: 247-251.
21. MacDonald DJ, Luo J, Saito T, Duong M, Bernier PL, Chiu RC, et al. Persistence of marrow stromal cells implanted into acutely infarcted myocardium: observations in a xenotransplant model. J Thorac Cardiovasc Surg 2005; 130: 1114-1121.
22. Waxman DJ, Chen L, Hecht JE, Jounaidi Y. Cytochrome p450-based cancer gene therapy: recent advances and future prospects. Drug Metab Rev 1999; 31: 503-522.
23. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995; 55: 581-589.
24. Chen L, Waxman DJ. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996; 56: 1331-1340.
25. Jounaidi Y, Hecht JED, Waxman DJ. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 1998; 58: 4391-4401.
26. Meer L, Janzer RC, Kleihues P, Kolar GF. In vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3, 3-dimethyl-1-triazeno)imidazole-4- carboxamide (DTIC). Biochem Pharmacol 1986; 35: 3243-3247.
27. Reid JM, Kuffel MJ, Miller JK, Rios R, Ames MM. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 1999; 5: 2192-2197.
28. Wang JS, Singh H, Zhang F, Ishizuka T, Deng H, Kemp R, et al. Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res 2006; 98: 962-969.
29. Wang JS, Zhang F, Jiang M, Wang MH, Zand BA, Abraham NG, et al. Transfection and functional expression of CYP4A1 and CYP4A2 using bicistronic vectors in vascular cells and tissues. J Pharmacol Exp Ther 2004; 311: 913-920.
30. Wang JS, Chen Z, Xia X, Lu D, Xue J, Ruan C, et al. Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34+ cells. Leuk Res 2002; 26: 281-288.
31. Wang JS, Chen Z, Xia X, Lu D, Xue J, Ruan C, et al. A bicistronic retroviral vector to introduce drug resistance gene into human umbilical cord blood CD34 + cells to improve combination chemotherapy tolerance. Chin Med J (Engl) 2001; 114: 25-29.
32. Jounaidi Y, Chen CS, Veal GJ, Waxman DJ. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol Cancer Ther 2006; 5: 541-555.